Search Results for “EC” – Page 161 – media

Does Loss of REM Sleep Affect Overall Health?

In a recently published paper, researchers outline the importance of REM sleep and the causes and consequences of loss of REM sleep.
- Source: medicalnewsbulletin
- 467
- November 29, 2017
REM Sleep Researches Sleep deprivation
How can you cope with seasonal affective disorder?

Seasonal affective disorder (SAD) is a type of depression that comes and goes with the four seasons, typically manifesting during the cold autumn and winter months, when the days are shorter, darker, and chillier.
- Source: medicalnewstoday
- 398
- November 27, 2017
Market Views SAD Seasonal affective disorder
Changes in diet may improve life expectancy in Parkinson’s patients

New research from the University of Aberdeen shows that weight loss in people with Parkinson's disease leads to decreased life expectancy, increased risk of dementia and more dependency on care.
- Source: medicalxpress
- 553
- November 27, 2017
Dementia Parkinson's Researches
China Food and Drug Administration Approves Gilead’s Sovaldi® (Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the China Food and Drug Administration (CFDA) has approved Sovaldi® (sofosbuvir 400mg), a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi was approved for the treatment of adults and adolescents (aged 12 to 18 years) infected with HCV genotype 1, 2, 3, 4, 5 or 6 as a component of a combination antiviral treatment regimen. Sovaldi is the first Gilead HCV medicine approved in China.
- Source: Gilead
- 770
- November 27, 2017
CFDA Gilead Sciences HCV New Approvals Sovaldi®
New cell death mechanism revealed

New research reveals how a dysfunction in the brain's so-called self-digestion system leads to cell death in neurodegenerative disorders. The newly discovered mechanism may lead to new therapies for conditions such as Parkinson's and Alzheimer's disease.
- Source: drugdu
- 711
- November 24, 2017
autophagy Dementia Huntington’s Disease neurodegenerative Parkinson's
Allegoric Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia

Allergan plc (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR™ (cariprazine) for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes of bipolar I disorder.
- Source: Allergan
- 470
- November 24, 2017
bipolar I disorder FDA schizophrenia VRAYLAR™
Pfizer and Genentech Duke it Out in Court Over Herceptin Biosimilar Patents

On Friday, November 17, Genentech, a Roche company, sued Pfizer in a federal court in Wilmington, Delaware, over Pfizer’s biosimilar for Genentech’s Herceptin. Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Genentech also is demanding compensation for lost sales if Pfizer launches its copycat version before the Herceptin patents expire.
- Source: Biospace
- 640
- November 24, 2017
biosimilar Company Insight FDA Genentech herceptin Pfizer Roche
Massachusetts’ Entasis Snags $31.9 Million To Advance Anti-infective Therapeutic Portfolio

“We welcome this strong support from a group of experienced and successful investors who understand the need and market opportunity for new medicines to combat multi drug-resistant bacterial infections”
- Source: biospace
- 478
- November 23, 2017
anti-infective drug-resistant Gram-negative infections Market Views
US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC

The latest BTD was granted for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor.
- Source: Roche
- 555
- November 23, 2017
anaplastic lymphoma kinase Company Insight FDA non-small cell lung cancer Roche
Using digital pills, researchers find patients consume fewer opioids than expected

The team found that most participants opted to use opioids during the first three days following discharge from the emergency department and that on average, patients took just six pills, despite being given 21.
- Source: Drugdeliverybusine
- 414
- November 23, 2017
etectRx‘s ID-Cap system opioid Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.